Your browser doesn't support javascript.
loading
Association of Incident Stroke Risk With an IL-18-Centered Inflammatory Network Biomarker Composite.
Martirosian, Richard A; Wiedner, Crystal D; Sanchez, Jasmin; Mun, Katherine T; Marla, Kiran; Teran, Cristina; Thirion, Marissa; Liebeskind, David S; McGrath, Emer R; Zucker, Jared M; Bernal, Rebecca; Beiser, Alexa S; DeCarli, Charles; Himali, Jayandra J; Seshadri, Sudha; Hinman, Jason D.
Affiliation
  • Martirosian RA; David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
  • Wiedner CD; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases (C.D.W., R.B., J.J.H., S.S.), University of Texas Health Science Center at San Antonio.
  • Sanchez J; David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
  • Mun KT; David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
  • Marla K; David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
  • Teran C; David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
  • Thirion M; David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
  • Liebeskind DS; David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
  • McGrath ER; Framingham Heart Study, MA (E.R.M.G., J.M.Z., A.S.B., C.D.C., J.J.H., S.S.).
  • Zucker JM; HRB Clinical Research Facility, School of Medicine, University of Galway, Ireland (E.R.M.G.).
  • Bernal R; Framingham Heart Study, MA (E.R.M.G., J.M.Z., A.S.B., C.D.C., J.J.H., S.S.).
  • Beiser AS; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases (C.D.W., R.B., J.J.H., S.S.), University of Texas Health Science Center at San Antonio.
  • DeCarli C; Framingham Heart Study, MA (E.R.M.G., J.M.Z., A.S.B., C.D.C., J.J.H., S.S.).
  • Himali JJ; Department of Neurology, Boston University School of Medicine, MA (A.S.B., J.J.H., S.S.).
  • Seshadri S; Department of Biostatistics, Boston University School of Public Health, MA (A.S.B., J.J.H.).
  • Hinman JD; Framingham Heart Study, MA (E.R.M.G., J.M.Z., A.S.B., C.D.C., J.J.H., S.S.).
Stroke ; 55(6): 1601-1608, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38690658
ABSTRACT

BACKGROUND:

A coordinated network of circulating inflammatory molecules centered on the pleotropic pro-atherogenic cytokine interleukin-18 (IL-18) is linked to cerebral small vessel disease. We sought to validate the association of this inflammatory biomarker network with incident stroke risk, cognitive impairment, and imaging metrics in a sample of the Framingham Offspring Cohort.

METHODS:

Using available baseline measurements of serum levels of IL-18, GDF (growth and differentiation factor)-15, soluble form of receptor for advanced glycation end products, myeloperoxidase, and MCP-1 (monocyte chemoattractant protein-1) from Exam 7 of the Framingham Offspring Cohort (1998-2001), we constructed a population-normalized, equally weighted log-transformed mean Z-score value representing the average level of each serum analyte to create an inflammatory composite score (ICS5). Multivariable regression models were used to determine the association of ICS5 with incident stroke, brain magnetic resonance imaging features, and cognitive testing performance.

RESULTS:

We found a significant association between ICS5 score and increased risk for incident all-cause stroke (hazard ratio, 1.48 [95% CI, 1.05-2.08]; P=0.024) and ischemic stroke (hazard ratio, 1.51 [95% CI, 1.03-2.21]; P=0.033) in the Exam 7 cohort of 2201 subjects (mean age 62±9 years; 54% female) aged 45+ years with an all-cause incident stroke rate of 6.1% (135/2201) and ischemic stroke rate of 4.9% (108/2201). ICS5 and its component serum markers are all associated with the Framingham Stroke Risk Profile score (ß±SE, 0.19±0.02; P<0.0001). In addition, we found a significant inverse association of ICS5 with a global cognitive score, derived from a principal components analysis of the neuropsychological battery used in the Framingham cohort (-0.08±0.03; P=0.019). No association of ICS5 with magnetic resonance imaging metrics of cerebral small vessel disease was observed.

CONCLUSIONS:

Circulating serum levels of inflammatory biomarkers centered on IL-18 are associated with an increased risk of stroke and cognitive impairment in the Framingham Offspring Cohort. Linking specific inflammatory pathways to cerebral small vessel disease may enhance individualized quantitative risk assessment for future stroke and vascular cognitive impairment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Interleukin-18 / Stroke / Inflammation Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Stroke Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Interleukin-18 / Stroke / Inflammation Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Stroke Year: 2024 Document type: Article
...